Table 2.
Myelofibrosis | N=57 |
---|---|
No pharmacological intervention | 26 (45.6%) |
Hydroxyurea | 8 (14%) |
Anagrelide | 3 (5.3%) |
Danazol | 3 (5.3%) |
Peginterferon alfa-2a | 3 (5.3%) |
Darbepoetin alfa | 2 (3.5%) |
Decitabine | 2 (3.5%) |
LBH589 | 2 (3.5%) |
Thalidomide | 2 (3.5%) |
Busulfan | 1 (1.8%) |
KB004 | 1 (1.8%) |
Luspatercept | 1 (1.8%) |
Melphalan | 1 (1.8%) |
Pomalidomide | 1 (1.8%) |
PRM-151 | 1 (1.8%) |
Non-myelofibrosis | N=16 |
Hydroxyurea | 10 (62.5%) |
Peginterferon alpha-2a | 4 (25%) |
Anagrelide | 2 (12.5%) |